Lung-MAP Continues to Adapt and Grow
It’s been a long time in the planning, but this week, it arrived.
Our Lung-MAP precision medicine trial has expanded and is now accepting patients with NSCLC – which make up about 85 percent of all lung cancer diagnoses in the U.S. This is, of course, good news for patients. Lung-MAP is now an option for thousands more. To get all the details about the trial expansion, and other big changes to the study, check out our press release here.
As you know, we launched Lung-MAP four years ago with much fanfare. It was the first large-scale lung cancer precision medicine trial backed by the NCI. It’s also the first major NCI cancer trial to test multiple treatments, simultaneously, under one “umbrella” or “master protocol” design.
It is also one of the first major public-private partnerships to coalesce around a publicly-funded clinical trial. Lung-MAP is a collaboration among four key players: NCI, SWOG Cancer Research Network, Friends of Cancer Research, and the Foundation for the National Institutes of Health (FNIH). But it is also involves others- Foundation Medicine, which manages trial tissue samples and now its liquid biopsies, 10 pharmaceutical companies, and several lung cancer advocacy organizations are now participants/supporters.
Lung-MAP still matters – for many reasons.
Its design has influenced nearly a dozen other studies – currently open, and under design. It has opened nine treatment sub-studies, with seven completed. The study has resulted in 25 publications and another 25 meeting abstracts. Most importantly, the trial has registered over 1,800 patients, and given hundreds of people across the country access to an exciting clinical research study. It has clearly advanced science, part of SWOG’s mission.
My biggest thanks to Mariah Norman and Crystal Miwa in our San Antonio operations office, and Stacey Adam and Amrin Chowdhury at FNIH, who shepherded through all of the many protocol changes required by this expansion, and to the Lung-MAP leadership team: Drs. Vassiliki Papadimitrakopoulou, David Gandara, Roy Herbst, and Mary Redman, among others. To our partners at NCI, FNIH, and Friends of Cancer Research – we thank you for creating something important with us.